Remisyonda olan ankilozan spondilit hastasında tedavi kararı

Hüseyin Turgut Elbek Özer

doi:10.19161/etd.863658

EN TR

Remisyonda olan ankilozan spondilit hastasında tedavi kararı

Abstract

Ankilozan spondilitte non-steroid anti-inflamatuvar ilaçlarda (NSAİİ) %9-35’e varan oranlarda anti-TNF ajanlarında %16-62 oranlarında remisyon sağlandığı görülmüştür. Biyolojik ilaç kesimini takiben bir yıl içerisinde hastalarda %47-76 oranlarında relaps görülmüştür. Remisyon sonrası doz azaltılması, tam doz tedavi devamı ile karşılaştırıldığında benzer oranlarda remisyon sürdürülmüştür (%53,5’e karşı %61,4). Ankilozan spondilitte NSAİİ’ın kullanımının radyolojik progresyonu gerilettiği ve azalmış mortalite ile ilişkili olduğu gösterilmiştir. NSAİİ’ın gerektiği durumlarda kullanılması önerilmektedir. Egzersiz programlarına remisyon sonrasında da devam edilmelidir.

Keywords

References

Poddubnyy D, Gensler LS. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol 2014 Oct; 28 (5): 807-18.
van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005; 52: 1205-15.
Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 2014; 73: 101-7.
van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT) Arthritis Rheum 2005;52:582-91.
Davis JC, Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-6.
van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-46.
Inman RD, Davis JC, Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58: 3402-12.
Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebocontrolled Phase 3 study. Ann Rheum Dis 2014; 73 (1):39-47.

Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009; 60: 946-54.
Song IH, Althoff CE, Haibel H, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis 2012; 71: 1212-5. 52 Ege Tıp Dergisi / Ege Journal of Medicine
Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with nonradiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1) Ann Rheum Dis 2013; 72: 815-22.
Dougados M, van der Heijde D, Sieper J, Braun J, et al. The symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2014 Aug; 66 (8): 2091-102.
Spadaro A, Lubrano E, Marchesoni A, et al. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. Rheumatology (Oxford) 2013 Oct; 52 (10): 1914-9.
Haibel H, Heldmann F, Braun J, Listing J, Kupper H, Sieper J. Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare. Arthritis Rheum 2013 65 (8): 2211-3.
Cantini F, Niccoli L, Cassarà E, Kaloudi O, Nannini C. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study. Biologics 2013; 7: 1-6.
Landewé R, Sieper J, Mease P, et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet 2018 Jul 14; 392 (10142): 134-44.
Moreno M, Gratacós J, Torrente-Segarra V, et al. REMINEA study Group. Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study. Arthritis Res Ther 2019 Apr 5; 21 (1):88.
Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. Maintained Clinical Remission in Ankylosing Spondylitis Patients Switched from Reference Infliximab to Its Biosimilar: An 18-Month Comparative OpenLabel Study. J Clin Med 2019 Jul 2; 8 (7). pii: E956. doi: 10.3390/jcm8070956.
Gratacós J, Pontes C, Juanola X, et al. REDES-TNF investigators. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis. Arthritis Res Ther 2019 Jan 8; 21 (1):11. doi: 10.1186/s13075-018-1772-z.
Carron P, Varkas G, Renson T, Colman R, Elewaut D, Van den Bosch F. High Rate of Drug-Free Remission After Induction Therapy With Golimumab in Early Peripheral Spondyloarthritis. Arthritis Rheumatol 2018 Nov; 70 (11): 1769-77.
Sieper J, Landewé R, Magrey M, et al. Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study. RMD Open 2019 Jun 7; 5 (1): e000917.
Wanders A, Heijde Dv, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005 Jun; 52 (6): 1756-65.
Kroon F, Landewé R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012 Oct; 71 (10): 1623-9.
Sieper J, Listing J, Poddubnyy D, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 2016 Aug; 75 (8): 1438-43.
Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 2011 Nov; 70 (11): 1921-5.
Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality: A Population-Based Study. Ann Intern Med 2015 Sep 15; 163 (6): 409-16.
Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken) 2019 Oct; 71 (10): 1285-99

Details

Primary Language

Turkish

Subjects

Health Care Administration

Journal Section

Case Report

Authors

Hüseyin Turgut Elbek Özer ^*
Türkiye

Publication Date

January 20, 2021

Submission Date

April 6, 2020

Acceptance Date

August 28, 2020

Published in Issue

Year 2021

DOI

https://doi.org/10.19161/etd.863658

IZ

https://izlik.org/JA65AN76DL

Cite

RIS / Bibtex

APA

Özer, H. T. E. (2021). Remisyonda olan ankilozan spondilit hastasında tedavi kararı. Ege Tıp Dergisi, 49-52. https://doi.org/10.19161/etd.863658

AMA

1.Özer HTE. Remisyonda olan ankilozan spondilit hastasında tedavi kararı. EJM. Published online January 1, 2021:49-52. doi:10.19161/etd.863658

Chicago

Özer, Hüseyin Turgut Elbek. 2021. “Remisyonda Olan Ankilozan Spondilit Hastasında Tedavi Kararı”. Ege Tıp Dergisi, January 1, 49-52. https://doi.org/10.19161/etd.863658.

EndNote

Özer HTE (January 1, 2021) Remisyonda olan ankilozan spondilit hastasında tedavi kararı. Ege Tıp Dergisi 49–52.

IEEE

[1]H. T. E. Özer, “Remisyonda olan ankilozan spondilit hastasında tedavi kararı”, EJM, pp. 49–52, Jan. 2021, doi: 10.19161/etd.863658.

ISNAD

Özer, Hüseyin Turgut Elbek. “Remisyonda Olan Ankilozan Spondilit Hastasında Tedavi Kararı”. Ege Tıp Dergisi. January 1, 2021. 49-52. https://doi.org/10.19161/etd.863658.

JAMA

1.Özer HTE. Remisyonda olan ankilozan spondilit hastasında tedavi kararı. EJM. 2021;:49–52.

MLA

Özer, Hüseyin Turgut Elbek. “Remisyonda Olan Ankilozan Spondilit Hastasında Tedavi Kararı”. Ege Tıp Dergisi, Jan. 2021, pp. 49-52, doi:10.19161/etd.863658.

Vancouver

1.Hüseyin Turgut Elbek Özer. Remisyonda olan ankilozan spondilit hastasında tedavi kararı. EJM. 2021 Jan. 1;49-52. doi:10.19161/etd.863658

Cited By

CURRENT TREATMENT APPROACHES IN ANKYLOSING SPONDILITIS

TURKISH MEDICAL STUDENT JOURNAL

https://doi.org/10.4274/tmsj.galenos.2023.2022-6-1

Treatment decision in patient with ankylosing spondylitis in remission

Abstract

Keywords

Remisyonda olan ankilozan spondilit hastasında tedavi kararı

Abstract

Keywords

References

Details

Primary Language

Subjects

Journal Section

Authors

Publication Date

Submission Date

Acceptance Date

Published in Issue

DOI

IZ

Cite

Cited By

CURRENT TREATMENT APPROACHES IN ANKYLOSING SPONDILITIS